To confirm that the MYC-mRNA drug achieved on-target inhibition of c-MYC in the primary tumor to achieve therapeutic efficacy, we performed H&E staining of the tumors (3) from the vector + nanocage, the 3× IC50, 6× IC50, and 9× IC50-treated tumor-bearing mice. This evidence concerns the gene MYC and neoplasm.